Targeting the mTOR pathway using novel ATP-competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma

Mechanistic target of rapamycin (mTOR), which functions via two multiprotein complexes termed mTORC1 and mTORC2, is positioned in the canonical phosphoinositide 3-kinase-related kinase (PI3K)/AKT (PI3K/AKT) pathways. These complexes exert their actions by regulating other important kinases, such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Anubhav G., Jeong, Seung Won, Gillick, John L., Sursal, Tolga, Murali, Raj, Gandhi, Chirag D., Jhanwar-Uniyal, Meena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448541/
https://www.ncbi.nlm.nih.gov/pubmed/34523696
http://dx.doi.org/10.3892/ijo.2021.5263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448541/
https://www.ncbi.nlm.nih.gov/pubmed/34523696
http://dx.doi.org/10.3892/ijo.2021.5263

Ejemplares similares